Ramiven (abemaciclib)
Ramiven (abemaciclib) – Breast Cancer Therapy in India
It is an anti-cancer drug indicated for specific types of breast cancer, primarily HR-positive, HER2-negative breast cancer, both locally advanced/metastatic and as adjuvant therapy for high-risk early-stage cases, used with other hormonal treatments. It works by blocking CDK4/6 proteins to slow cancer cell growth and prevent recurrence.
| Brand Name: | Ramiven |
| Generic Name: | Abemaciclib Tablets |
| Strength: | • Tablets: 150 mg |
| Manufacturer: | Lilly |
| Approved By: | EMA, USFDA |
Source Details: Patient Information.
Ramiven must always be used under the supervision of a Registered Medical Practitioner (RMP).
Access Ramiven for Breast Cancer
Abemaciclib, sold under the brand name Ramiven 150 mg, is available in India. Patients can access this medicine for personal use through authorized channels. IPN, New Delhi serves as a facilitator for the procurement of specialized drugs on behalf of patients or treating doctors. To proceed, the applicant must submit an application with a valid prescription issued by a Registered Medical Practitioner (RMP).
For any queries, including information regarding the cost of the pharmaceutical product in India, please contact the IPN Healthcare Support Team via email or at the following numbers: Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774.
Contact Info
CORPORATE OFFICE:
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
EMAIL ID:
Abemaciclib, sold under the brand name Ramiven among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.
Since September 2017, abemaciclib has been approved in the US for "adults who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after taking therapy that alters a patient's hormones".
In studies that compared fulvestrant plus abemaciclib to fulvestrant plus placebo in breast cancer patients, progression-free survival under abemaciclib therapy was 16.4 months on average, as compared to 9.3 months under the placebo arm.
Contact IPN – Ramiven Access in India
For inquiries regarding availability, import process, or cost of Ramiven (abemaciclib):
India Pharma Network (IPN) : Headquartered in New Delhi, with branch offices in Delhi, Gurugram, Mumbai, Bangalore, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur and Lucknow, IPN supports medicine imports across India on a Named Patient Basis and for personal use only. Mobile/WhatsApp: Mr. Tarun: +91 9891 296 838 | Mr. Neeraj: +91 9811 747 774. Email: info@indianpharmanetwork.co.in
NEWS/UPDATES
- Eli Lilly introduces Ramiven (abemaciclib) in India.
- Eli Lilly introduces medication for early stage breast cancer.
- Eli Lilly unveils DCGI approved Ramiven in India for early stage breast cancer.
Compliance & Disclaimer
India Pharma Network acts solely as a facilitator for Ramiven (abemaciclib) access. IPN does not manufacture, sell, or promote medicines and does not provide medical advice. All imports are:
- Strictly on a Named Patient Basis
- Exclusively for personal use
- Not for resale, distribution, or commercial sale
- Subject to applicable Indian laws and regulatory approvals
The prescribing physician remains solely responsible for dosage, therapy, and clinical decisions.
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa
Mobile / WhatsApp / Phone
M: +91 9811747774, 9891296838.
P: +91-11-26532129 / 26536398
Free Customer Support
info@indianpharmanetwork.co.in
urgent@indianpharmanetwork.co.in